Abstracts tagged "Atherosclerosis"

Abstract Number: 1573 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna Gladman ², Jiandong Su ¹, Vernon Farewell ³, Jorge Sanchez-Guerrero ⁴, Juanita Romero-Diaz ⁵, Sang-Cheol Bae ⁶, Paul Fortin ⁷, Ola Nived ⁸, Ann E Clarke ⁹, Sasha Bernatsky ¹⁰, Caroline Gordon ¹¹, John Hanly ¹², Daniel J Wallace ¹³, David A Isenberg ¹⁴, Anisur Rahman ¹⁵, Joan Merrill ¹⁶, Ellen M Ginzler ¹⁷, Graciela Alarcon ¹⁸, Michelle Petri ¹⁹, Ian Bruce ²⁰, Munther A Khamashta ²¹, Cynthia Aranow ²², Susan Manzi ²³, MA Dooley ²⁴, Rosalind Ramsey-Goldman ²⁵, Andreas Jönsen ⁸, Kristjan Steinsson ²⁶, Asad Zoma ²⁷, Guillermo Ruiz-Irastorza ²⁸, S Sam Lim ²⁹, Kenneth C Kalunian ³⁰, Murat Inanc ³¹, Ronald van Vollenhoven ³², Manuel Ramos ³³, Diane Kamen ³⁴, Soren Jacobsen ³⁵, Christine Peschken ³⁶, Anca Askanase ³⁷ and Thomas Stoll ³⁸, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University of Cambridge, Cambridge, United Kingdom, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ⁸Lund University, Lund, Sweden, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹¹University of Birmingham, Birmingham, United Kingdom, ¹²Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ¹³Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹⁴Centre for Rheumatology, London, United Kingdom, ¹⁵University College London, London, United Kingdom, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁸The University of Alabama at Birmingham, Birmingham, AL, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²¹King's College London School of Medicine, London, United Kingdom, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Allegheny Health Network, Pittsburg, PA, ²⁴UnC Kidney Centre, Chapel Hill, NC, ²⁵Northwestern University, Chicago, IL, ²⁶Landspitali, University Hospital, Reykjavik, Iceland, ²⁷Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ²⁸Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Bizkaia, Spain, ²⁹Emory University, Atlanta, GA, ³⁰UC San Diego School of Medicine, LaJolla, CA, ³¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³³Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³⁴Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶University of Manitoba, Winnipeg, Canada, ³⁷Columbia University Medical Center, New York, NY, ³⁸University of Glasgow, Kilbride, Scotland, United Kingdom
Background/Purpose: The prevalence of atherosclerotic vascular events (AVE) in published literature of an inception cohort with SLE is 10%. We aimed to investigate the accrual…
Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Silvia Rollefstad¹, Till Uhlig^2,3, Lars Fridtjof Karoliussen³, Hilde B. Hammer⁴ and Anne Grete Semb⁵, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…
Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Lihi Eder¹, Vinod Chandran², Iain B. McInnes³, Richard J. Cook⁴, Dafna D Gladman⁵, Paul Welsh⁶, Naveed Sattar⁷ and Paula Harvey⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…
Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
Lihi Eder¹, Paula Harvey², Paul Welsh³, Vinod Chandran⁴, Iain B. McInnes⁵, Richard J. Cook⁶, Dafna D Gladman⁷ and Naveed Sattar⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵University of Glasgow, Glasgow, United Kingdom, ⁶Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…
Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Curtis Sobchak¹, Shadi Akhtari², Paula Harvey², Dafna D Gladman³, Vinod Chandran⁴, Richard J. Cook⁵ and Lihi Eder⁶, ¹Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…
Abstract Number: 1650 • 2018 ACR/ARHP Annual Meeting
Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
Tomas Cazenave¹, Maria Celeste Orozco², Gustavo Citera³, Emilce E Schneeberger¹ and Marcos G. Rosemffet², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina
Background/Purpose: There is evidence that shows an increased cardiovascular risk in patients with Axial Spondyloarthritis (axSpA). Ultrasonography (US) is a simple imaging tool used to…
Abstract Number: 1848 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors in Adults with Juvenile Idiopathic Arthritis in Sustained Remission
Ivan Arias de la Rosa¹, Inmaculada Concepcion Aranda-Valera², Rosa Roldan², Maria Carmen Abalos-Aguilera¹, Maria Dolores de la Rosa-Garrido², Yolanda Jiménez-Gómez³, Carlos Perez-Sanchez³, Alejandro Escudero-Contreras¹, Chary Lopez-Pedrera², Eduardo Collantes-Estévez³ and Nuria Barbarroja³, ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the more common chronic diseases of childhood that often persists into adulthood and can result in significant…
Abstract Number: 2816 • 2018 ACR/ARHP Annual Meeting
Development of a Microrna Panel for Predicting Coronary Atherosclerosis in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus¹, Quanhu Sheng¹, Fei Ye¹, Yan Guo¹, Qiong Wu¹, Annette M. Oeser¹, Ryan Allen¹, Paolo Raggi², Kasey Vickers¹ and C Michael Stein¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), regulate gene expression and can be used as biomarkers of disease. Patients with rheumatoid arthritis (RA)…
Abstract Number: 68 • 2018 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis
Raquel Lopez-Mejías¹, Fernanda Genre¹, Sara Remuzgo-Martínez¹, David Carmona^2,3, Verónica Pulito-Cueto¹, Carlos González-Juanatey⁴, Alfonso Corrales¹, Esther Vicente⁵, Jose A. Miranda-Filloy⁶, Beatriz-Segura Tejera⁷, Marco A. Ramírez Huaranga⁸, Verónica Mijares¹, Leticia Lera-Gomez¹, Ricardo Blanco¹, Montserrat Robustillo-Villarino⁹, Javier Rodríguez-Carrio¹⁰, Ana Suárez¹⁰, Mercedes Alperi-López¹¹, Francisco Javier Ballina-García¹², Francisco Javier López Longo¹³, Francisco Javier Narváez¹⁴, Juan José Alegre⁹, Antonio Mera¹⁵, Eva Perez Pampín¹⁶, Antonio Gonzalez¹⁷, Enrique Raya Álvarez¹⁸, Chary López-Pedrera¹⁹, Carmen Gomez Vaquero¹⁴, Alejandro Balsa²⁰, Dora Pascual-Salcedo²⁰, Patricia Carreira²¹, Isidoro Gonzalez-Alvaro⁵, Luis Rodriguez Rodriguez²², Benjamin Fernandez Gutierrez²², Ivan Ferraz-Amaro²³, Santos Castañeda²⁴, Javier Martin³, Javier Llorca²⁵ and Miguel Angel González-Gay^1,26,27, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada, Spain, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ⁴Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁵Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁶Rheumatology Department, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁷Rheumatology Division, Hospital Insular de Gran Canaria, Las Palmas, Spain, ⁸Rheumatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ⁹Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁰Area of Immunology, Department of Functional Biology, University of Oviedo, Oviedo, Spain, ¹¹Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ¹²Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹³Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain, ¹⁵Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁶Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁷Laboratorio Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁸Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ¹⁹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²⁰Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²¹Servicio de Reumatología, Hospital Universitario, Madrid, Spain, ²²Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ²³Rheumatology Division, Hospital Insular de Gran Canaria, La Laguna, Spain, ²⁴Rheumatology, Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ²⁵School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ²⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ²⁷Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Cardiovascular (CV) disease is the most common cause of morbidity and mortality in patients with rheumatoid arthritis (RA) [1, 2]. Traditional CV risk factors…
Abstract Number: 2818 • 2018 ACR/ARHP Annual Meeting
Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Panagiota Anyfanti¹, Eugenia Gkaliagkousi¹, Areti Triantafyllou¹, Eleni Gavriilaki¹, Panagiotis Dolgyras¹, Sophia Chatzimichailidou², Vasiliki Galanopoulou³, Stella Douma¹ and Spyros Aslanidis², ¹3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ²Rheumatology Department-2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ³Rheumatology Department, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece
Background/Purpose: Galectin-3 has emerged as a promising novel biomarker of cardiovascular fibrosis, that can improve cardiovascular risk stratification in high-risk populations. Rheumatoid arthritis (RA) is…
Abstract Number: 497 • 2018 ACR/ARHP Annual Meeting
Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
Ilana Golub¹, Jennifer Wang², Ani Shahbazian¹, John Moriarty¹ and Christina Charles-Schoeman³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a marked increase in cardiovascular (CV) morbidity and mortality compared to the general population. Conventional lipid profiles are…
Abstract Number: 2827 • 2018 ACR/ARHP Annual Meeting
Remission Targets and Prevention of Subclinical Atherosclerosis in Psoriatic Arthritis- Which Target Should We Choose?
Isaac T. Cheng¹, Qing Shang², Edmund Kwok Ming Li², Priscilla Wong¹, Lydia Ho Pui Tam², Tracy Y. Zhu³, M Mimi Chang⁴, JW Jack LEE⁵, PW Alex Lee² and Lai-Shan Tam⁴, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Bone Quality and Health Centre of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ⁴Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Systemic inflammation contributes to the excess risk of cardiovascular disease (CVD) in PsA. We had demonstrated that achieving sustained minimal disease activity (sMDA) was…
Abstract Number: 499 • 2018 ACR/ARHP Annual Meeting
Low Inflammatory Burden and Statin Exposure Inhibit Progression and Induce Regression of Early Coronary Plaques in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Early atherosclerotic lesions appear as non-calcified plaques (NCP) on a non-invasive coronary artery evaluation by computed tomography angiography (CCTA). Advanced, more vulnerable lesions appear…
Abstract Number: 500 • 2018 ACR/ARHP Annual Meeting
Impact of Inflammation and Biologic Treatments on Generation and Progression to Advanced Calcified Coronary Plaques in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: In early atherogenesis inflammation drives and co-localizes with intimal calcification. In chronic, advanced plaques inflammation and calcification are inversely correlated and spatially distinct; advanced…
Abstract Number: 501 • 2018 ACR/ARHP Annual Meeting
Predictors of Change in Coronary Plaque Burden and Composition in Patients with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Cardiology, Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: We previously reported higher prevalence, burden and more vulnerable occult coronary plaque composition in patients with rheumatoid arthritis (RA) compared to age and gender-matched…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].